Abstract
Micromet AG and MedImmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia. © The Thomson Corporation.
| Original language | English |
|---|---|
| Pages (from-to) | 62-68 |
| Number of pages | 6 |
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 8 |
| Issue number | 1 |
| Publication status | Published - Feb 2006 |
